Cargando…
The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children
Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) in endemic areas. Although the live attenuated SA 14-14-2 JE vaccine (LAJEV) has been widely used since its introduction, the systemic data of LAJEV was very rarely available in Korea. We conducted the...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414646/ https://www.ncbi.nlm.nih.gov/pubmed/25931793 http://dx.doi.org/10.3346/jkms.2015.30.5.612 |
_version_ | 1782368976460840960 |
---|---|
author | Kwon, Hyo Jin Lee, Soo Young Kim, Ki Hwan Kim, Dong Soo Cha, Sung Ho Jo, Dae Sun Kang, Jin Han |
author_facet | Kwon, Hyo Jin Lee, Soo Young Kim, Ki Hwan Kim, Dong Soo Cha, Sung Ho Jo, Dae Sun Kang, Jin Han |
author_sort | Kwon, Hyo Jin |
collection | PubMed |
description | Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) in endemic areas. Although the live attenuated SA 14-14-2 JE vaccine (LAJEV) has been widely used since its introduction, the systemic data of LAJEV was very rarely available in Korea. We conducted the open-label, prospective cohort study to assess the immunogenicity and safety of this vaccine. Ninety subjects were enrolled, and LAJEV in a 2-dose primary series was given with a 12-month interval. Neutralizing antibody titers were measured before and after each vaccination, and active monitoring for adverse events was performed. After the first dose, 91.1% of subjects had seroprotection with a geometric mean titer (GMT) of 40.9. Seroprotection rate after the second dose was 97%, and GMT showed an increase of 6.5-fold. Most adverse events following immunization were self-limited, and no serious adverse events were reported until 42 days after each dose. The 2-dose administration of LAJEV in the primary immunization schedule appeared to be highly immunogenic and safe. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-4414646 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | The Korean Academy of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-44146462015-05-01 The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children Kwon, Hyo Jin Lee, Soo Young Kim, Ki Hwan Kim, Dong Soo Cha, Sung Ho Jo, Dae Sun Kang, Jin Han J Korean Med Sci Original Article Effective and tolerable vaccination is an essential strategy to prevent Japanese encephalitis (JE) in endemic areas. Although the live attenuated SA 14-14-2 JE vaccine (LAJEV) has been widely used since its introduction, the systemic data of LAJEV was very rarely available in Korea. We conducted the open-label, prospective cohort study to assess the immunogenicity and safety of this vaccine. Ninety subjects were enrolled, and LAJEV in a 2-dose primary series was given with a 12-month interval. Neutralizing antibody titers were measured before and after each vaccination, and active monitoring for adverse events was performed. After the first dose, 91.1% of subjects had seroprotection with a geometric mean titer (GMT) of 40.9. Seroprotection rate after the second dose was 97%, and GMT showed an increase of 6.5-fold. Most adverse events following immunization were self-limited, and no serious adverse events were reported until 42 days after each dose. The 2-dose administration of LAJEV in the primary immunization schedule appeared to be highly immunogenic and safe. GRAPHICAL ABSTRACT: [Image: see text] The Korean Academy of Medical Sciences 2015-05 2015-04-15 /pmc/articles/PMC4414646/ /pubmed/25931793 http://dx.doi.org/10.3346/jkms.2015.30.5.612 Text en © 2015 The Korean Academy of Medical Sciences. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Kwon, Hyo Jin Lee, Soo Young Kim, Ki Hwan Kim, Dong Soo Cha, Sung Ho Jo, Dae Sun Kang, Jin Han The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children |
title | The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children |
title_full | The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children |
title_fullStr | The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children |
title_full_unstemmed | The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children |
title_short | The Immunogenicity and Safety of the Live-attenuated SA 14-14-2 Japanese Encephalitis Vaccine Given with a Two-dose Primary Schedule in Children |
title_sort | immunogenicity and safety of the live-attenuated sa 14-14-2 japanese encephalitis vaccine given with a two-dose primary schedule in children |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414646/ https://www.ncbi.nlm.nih.gov/pubmed/25931793 http://dx.doi.org/10.3346/jkms.2015.30.5.612 |
work_keys_str_mv | AT kwonhyojin theimmunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren AT leesooyoung theimmunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren AT kimkihwan theimmunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren AT kimdongsoo theimmunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren AT chasungho theimmunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren AT jodaesun theimmunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren AT kangjinhan theimmunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren AT kwonhyojin immunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren AT leesooyoung immunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren AT kimkihwan immunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren AT kimdongsoo immunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren AT chasungho immunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren AT jodaesun immunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren AT kangjinhan immunogenicityandsafetyoftheliveattenuatedsa14142japaneseencephalitisvaccinegivenwithatwodoseprimaryscheduleinchildren |